Literature DB >> 8519632

Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure.

A Zoubek1, H A Zaunschirm, T Lion, G Fischmeister, G Vollnhofer, H Gadner, K Pillwein, A Schalhorn, U Bode.   

Abstract

We report on an 18.5-year-old woman with osteosarcoma and delayed methotrexate (MTX) elimination due to renal failure after high-dose MTX, in whom rescue with high doses of folinic acid caused intolerable side effects. In this life-threatening clinical situation, the patients was rescued by the administration of recombinant carboxypeptidase G2, a bacterial enzyme that rapidly hydrolyzes MTX into inactive metabolites. This is the first report on the successful clinical use of this alternative catabolic route for the elimination of MTX.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8519632     DOI： 10.3109/08880019509009477

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN： 0888-0018            Impact factor:   1.969


  8 in total

1.  Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.

Authors:  Brigitte C Widemann; Frank M Balis; AeRang Kim; Matthew Boron; Nalini Jayaprakash; Aiman Shalabi; Michelle O'Brien; Michelle Eby; Diane E Cole; Robert F Murphy; Elizabeth Fox; Percy Ivy; Peter C Adamson
Journal:  J Clin Oncol       Date:  2010-08-02       Impact factor: 44.544

2.  Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.

Authors:  Jeffrey R Scott; Yinmei Zhou; Cheng Cheng; Deborah A Ward; Hope D Swanson; Alejandro R Molinelli; Clinton F Stewart; Fariba Navid; Sima Jeha; Mary V Relling; Kristine R Crews
Journal:  Pediatr Blood Cancer       Date:  2015-01-28       Impact factor: 3.167

Review 3.  Folate, antifolates, and folate analogs in pediatric oncology.

Authors:  M C Hum; B A Kamen
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

4.  Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.

Authors:  Anthony M Christensen; Jennifer L Pauley; Alejandro R Molinelli; John C Panetta; Deborah A Ward; Clinton F Stewart; James M Hoffman; Scott C Howard; Ching-Hon Pui; Alberto S Pappo; Mary V Relling; Kristine R Crews
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

5.  Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure.

Authors:  S Buchen; D Ngampolo; R G Melton; C Hasan; A Zoubek; G Henze; U Bode; G Fleischhack
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640

Review 6.  Drugs and pharmaceuticals: management of intoxication and antidotes.

Authors:  Silas W Smith
Journal:  EXS       Date:  2010

7.  MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.

Authors:  Zachary L Taylor; Tomoyuki Mizuno; Nieko C Punt; Balaji Baskaran; Adriana Navarro Sainz; William Shuman; Nicholas Felicelli; Alexander A Vinks; Jesper Heldrup; Laura B Ramsey
Journal:  Clin Pharmacol Ther       Date:  2020-07-18       Impact factor: 6.875

8.  Glucarpidase to combat toxic levels of methotrexate in patients.

Authors:  Jacalyn M Green
Journal:  Ther Clin Risk Manag       Date:  2012-11-22       Impact factor: 2.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.